The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality (Q90799655)
Jump to navigation
Jump to search
scientific article published on 29 March 2020
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality |
scientific article published on 29 March 2020 |
Statements
The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality (English)
Chi Zhang
Zhao Wu
Jia-Wen Li
Gui-Qiang Wang